

## County Durham and Darlington Area Prescribing Committee

Summary of decisions made regarding new product requests considered via email by Committee due to cancellation of meeting on **Thursday 1st March 2018**

### Classification of products:

- G** **Green drug** - Can be initiated and prescribed in all care settings **G-** Second line / alternative green drug
- G+** **Green+ drug** Specialist initiation / recommendation. Can be recommended by a specialist for initiation in primary care; or be initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.
- A** **Amber drug** - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care
- R** **Red drug** - Drugs that should remain under the total responsibility of the specialist. Usually considered as "hospital only" drugs
- X** **Not Approved** - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within County Durham & Darlington.
- ⊘** **Not Reviewed** - Drugs that haven't been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in County Durham & Darlington.
- **Unclassed Drug** - Drugs that do not fall into one of the above categories

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>1) Requests deferred from previous meetings</b>				
None				
<b>2) New Requests</b>				
None				
<b>3) New formulations &amp; extensions to use</b>				
None				
<b>5) Products considered by NICE</b>				
TA492 Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA493 Cladribine tablets for treating relapsing–remitting multiple sclerosis	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>TA494 Naltrexone–bupropion for managing overweight and obesity</b>		✓		The formulary will reflect the TAG – NHS England is the responsible commissioner – NICE did not recommend use.
<b>TA495 Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer</b>	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA496 Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer</b>	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA497 Golimumab for treating non-radiographic axial spondyloarthritis</b>	✓ R			The formulary will reflect the TAG – CCG is the responsible commissioner.
<b>TA498 Lenvatinib with everolimus for previously treated advanced renal cell carcinoma</b>	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA499 Glecaprevir–pibrentasvir for treating chronic hepatitis C</b>	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA500 Ceritinib for untreated ALK-positive non-small-cell lung cancer</b>	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA502 Ibrutinib for treating relapsed or refractory mantle cell lymphoma</b>	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>TA503 Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer</b>		✓		The formulary will reflect the TAG – NHS England is the responsible commissioner – NICE did not recommend use.
<b>6) Northern (NHS) Treatment Advisory Group (N-TAG )</b>				
None				
<b>7) Appeals against earlier decisions by the APC</b>				
None				
<b>8) Miscellaneous decisions by the APC</b>				
<b>PR Freeze Spray</b>				<b>Decision:</b> Agreed to remove from Chapter 10 as should only be in Chapter 15 as only on formulary for use to test if local anaesthetic has worked.
<b>Biotene/Bioxantra</b>	✓ 			<b>Decision:</b> Both should have same formulary status for saliva replacement.
<b>Sodium Cromoglycate 2% eye drops</b>				<b>Decision:</b> Agreed to remove from formulary due to increased cost and use not generally recommended in guidelines for the management of allergic rhinitis.

The following guidelines were presented to and approved at the March 2018 meeting of the APC:

- Nil

The following Green+ drug information leaflets were presented to and approved at the March 2018 meeting of the APC:

- Nil

The following shared care guidelines were presented to and approved at the March 2018 meeting of the APC:

- Nil